Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    Context Therapeutics

    MCap

    USD16m

    Last close

    USD1.00

    ▲ 0.32 (47.06%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Sareum Holdings (AIM: SAR)

Currency in GBP

Last close As at 06/02/2023

GBP1.93

▲ 8.00 (4.34%)

Market capitalisation

GBP125m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare

Sareum Holdings — SDC-1801 CTA application hits a roadblock

Sareum Holdings — SDC-1801 poised for the clinic

Sareum Holdings — Sierra Oncology returns rights to SRA737

Healthcare

Sareum Holdings — Sotyktu approval positive read-across for SDC-1801
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Share Price Performance

Financials

Sareum has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has turned down the clinical trial authorisation (CTA) for SDC-1801 based on the submitted data package. While Sareum awaits the formal letter of non-acceptance, initial insights suggest that the MHRA will seek a review by the UK Good Laboratory Practice Monitoring Authority or request additional information to support the submitted non-clinical data. As a reminder, Sareum filed the CTA for SDC-1801 in July 2022 with the intention of commencing the Phase Ia trial in Q4 CY22. While the company is seeking further clarification from the MHRA on the requirements for resubmission, we now anticipate a delay in launching clinical activity.

Research

View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free